In 2016, CELLINK revolutionized bioprinting by releasing the first universal bioink and subsequently launching the world’s first affordable 3D bioprinter. Since our inception, we have been committed to meeting our customers’ needs by producing versatile, high-quality and easy-to-use systems and solutions. As industry leaders in bioprinting with the world’s most robust portfolio of systems, materials, and services, we aim to facilitate the paradigm shift of 3D cell culture. Our technology enables the printing of human tissues, which enable faster and more accurate models for drug development, while replacing animal experiments.

Today, CELLINK’s solutions are cited in 1400+ publications and are trusted by 1,600+ academic, pharmaceutical and industrial labs.